Clinical Trials, Drug Manufacturers

Solid Formulation of a Recombinant Anthrax Vaccine

By Glide Technologies

Pfenex and Glide Pharma have an ongoing collaboration to develop an anthrax vaccine containing the recombinant protective antigen (rPA) from Bacillus anthracis produced using Pfēnex expression technology, which is suitable for delivery with the Glide SDI (solid dose injection) technology.

This approach will address two important logistical constraints of the currently available vaccine, namely, long term stability during storage at room temperature and ease of administration.

Download to find out more.

Enter your details below to view the free white paper

By downloading this whitepaper, you acknowledge that GlobalData may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.